Health Care • Biotechnology: Pharmaceutical Preparations
$1.04 ▼ -0.05
(-4.59%)
MKT CAP: $27.8M • VOL: 34.9K
52W L $1 52W H $3
ROARABLE / RQD
E • 34/100
PIOTROSKI
1 / 9
ABVC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $509.6K | $152.4K |
| YoY Revenue Growth % | — | +234.3% | — |
| Gross Profit | — | $508.8K | — |
| Gross Margin % | — | 98.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.2M | -$4.7M | -$6.8M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | -$7.9M | -$4.9M | -$7.8M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$3.0M | -$1.8M | -$4.2M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$3.0M | -$1.8M | -$4.2M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $681.5K | $248.4K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $11.1M | $1.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ABVC.